SonaCare Medical Receives FDA Clearance for its Sonablate High Intensity Focused Ultrasound Prostate Ablation Device

SonaCare Medical Receives FDA Clearance for its Sonablate High Intensity Focused Ultrasound Prostate Ablation Device

Press releases may be edited for formatting or style | October 13, 2015
CHARLOTTE, NC (PRWEB) OCTOBER 13, 2015 -- SonaCare Medical, LLC, a pioneer in minimally invasive high intensity focused ultrasound (HIFU) technologies, announced today that it received de novo clearance from the U.S. Food and Drug Administration (FDA) to market the Sonablate® 450 in the U.S. for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation. SonaCare Medical expects to begin U.S. distribution this October.

“The FDA regulatory authorization to market Sonablate® in the U.S. is a milestone for non-invasive prostate care and a tremendous gain for men’s health,” said Mark Carol, MD, Chief Executive Officer of SonaCare Medical. “Men all over the world, in the more than 49 countries where it has already been authorized for use, have had access to this technology for prostate ablation. There are numerous peer reviewed articles attesting to its value in ablating the prostate while minimizing the occurrence of side effects. Our company is appreciative of the collaborative efforts made on the part of the FDA to bring this technology to the U.S.”

Sonablate® trial investigator Michael Koch, MD, Chairman of the Department of Urology at Indiana University comments, “I believe that we are at a pivotal point in prostate care. Simultaneous advances in imaging, fusion technologies, and now more focused therapies are going to allow us to precisely diagnose prostate conditions, and ablate these targeted areas rather than perform whole gland prostate surgery, which carries a significant burden on quality of life. HIFU will become the work-horse of subtotal prostate therapy.”

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

Herbert Lepor, MD, Professor and Martin Spatz Chairman, Department of Urology NYU School of Medicine, who also participated in the Sonablate® trial, further comments, “HIFU is a novel technology that has been used worldwide to ablate prostate tissue. Until now, this technology was not available in the U.S. It is anticipated that ablative urological surgeons in the U.S. will quickly master and adapt this technology for their patients. HIFU offers the opportunity for the precise delivery of ablative energy to the prostate. Thus, it can be adapted to whole gland or focal gland ablation.”

“The FDA’s decision on Sonablate® is an important step in providing men with prostate conditions access to this less invasive approach. We hope that focused ultrasound will eventually become a standard of care for treating the prostate,” said Neal Kassell, MD, Chairman of the Focused Ultrasound Foundation.

You Must Be Logged In To Post A Comment